Revance Therapeutics, Inc.

Rachunek Zysków i Strat


Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna



Przychody TTM (mln): 247
EBIT TTM (mln): -156
index 0 1 2 3 4 5 6 7 8 9 10 11 12
Rok finansowy 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Przychód (mln) 1 1 1 0 0 0 0 4 0 15 78 133 234
Przychód Δ r/r 0.0% 28.7% -13.9% -37.9% -21.7% 0.0% -12.7% 1323.3% -88.9% 3610.7% 407.7% 70.4% 76.5%
Marża brutto 99.1% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% -24805.8% 68.9% 69.9% 61.0% 62.4%
EBIT (mln) -28 -43 -38 -52 -72 -88 -120 -143 -164 -273 -275 -272 -221
EBIT Δ r/r 0.0% 55.7% -11.5% 36.2% 38.9% 22.0% 36.5% 18.4% 15.3% 66.1% 0.6% -0.9% -18.9%
EBIT (%) -4979.9% -6023.2% -6195.3% -13590.1% -24105.7% -29405.0% -45963.4% -3825.0% -39820.6% -1782.5% -353.1% -205.3% -94.3%
Koszty finansowe (mln) 18 29 15 11 1 1 0 0 0 15 6 16 19
EBITDA (mln) -26 -42 -39 -52 -72 -79 -117 -139 -159 -263 -261 -242 -207
EBITDA(%) -4590.7% -5789.1% -6260.5% -13639.7% -24137.7% -26173.7% -44508.4% -3737.8% -38554.5% -1718.5% -335.6% -182.3% -88.5%
Podatek (mln) 18 29 13 8 -1 -1 -2 3 -3 -3 6 1 0
Zysk Netto (mln) -45 -58 -52 -63 -73 -89 -121 -143 -156 -282 -287 -356 -324
Zysk netto Δ r/r 0.0% 29.9% -10.0% 20.0% 16.8% 21.5% 35.1% 18.2% 9.6% 80.6% 1.7% 24.3% -9.1%
Zysk netto (%) -8054.4% -8125.4% -8500.5% -16427.4% -24492.0% -29756.7% -46025.6% -3823.2% -37824.9% -1840.7% -368.7% -268.9% -138.4%
EPS -6.25 -8.12 -2.96 -3.24 -3.02 -3.18 -4.01 -3.94 -3.59 -4.86 -4.25 -4.9 -3.83
EPS (rozwodnione) -6.25 -8.12 -2.96 -3.24 -3.02 -3.18 -4.01 -3.94 -3.59 -4.86 -4.25 -4.9 -3.83
Ilośc akcji (mln) 7 7 18 19 24 28 30 36 43 58 68 73 85
Ważona ilośc akcji (mln) 7 7 18 19 24 28 30 36 43 58 68 73 85
Waluta USD USD USD USD USD USD USD USD USD USD USD USD USD